Login
$NVS
$160.20 +$0.00 (0.0%) After hours

Company Executives

Officer In this role Source
Vasant (Vas) Narasimhan
Chief Executive Officer
Since 2018
8 years
Harry Kirsch
Chief Financial Officer
Since 2013
13 years
Shreeram Aradhye
President, Development, and Chief Medical Officer
Since 2022
4 years
Aharon (Ronny) Gal
Chief Strategy & Growth Officer
Since 2022
4 years
Karen L. Hale
Chief Legal and Compliance Officer
Since 2025
1 year
Rob Kowalski
Chief People & Organization Officer
Since 2021
5 years
Victor Bulto
President, US
Since 2022
4 years
Patrick Horber
President, International
Since 2023
3 years
Steffen Lang
President, Operations
Since 2022
4 years
Fiona H. Marshall
President, Biomedical Research
Since 2022
4 years

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the 20-F annual report

Directors
12
serving now
Average tenure
6.0 years
from year joined
CEO also chairs the board
No
Giovanni Caforio
Director On board Committees Source
Giovanni Caforio
2025
1 year
None stated
Simon Moroney
2020
6 years
Compensation Committee · Chair
Nancy C. Andrews
2015
11 years
None stated
Ton Buechner
2016
10 years
None stated
Patrice Bula
2019
7 years
Compensation Committee
Elizabeth (Liz) Doherty
2016
10 years
Audit and Compliance Committee · Chair
Bridgette Heller
2020
6 years
Compensation Committee
Daniel Hochstrasser
2022
4 years
None stated
Frans van Houten
2017
9 years
None stated
Elizabeth McNally
2025
1 year
None stated
Ana de Pro Gonzalo
2022
4 years
Audit and Compliance Committee
John D. Young
2023
3 years
Compensation Committee

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. NOVARTIS AG has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support